December 1

Fisch Highlights Patient Case of Relapse Following Gilteritinib Treatment in FLT3-TKD+ AML

November 29, 2019

Clinical Articles

Following the FDA’S approval of gilteritinib in November 2018, adult patients with FLT3-mutant acute myeloid leukemia were able to receive the FLT3 tyrosine kinase inhibitor when they relapsed or became refractory to a prior therapy. The agent has demonstrated promising efficacy in the population of patients with AML harboring FLT3 mutations.

Dynamic Tumor Cell Profiling Technique Moves Therapy Beyond Genomics

November 30, 2019

Clinical Articles

A technique involving BH3 profiling is emerging as a promising drug discovery tool for assessing whether a tumor is primed for cell death and would respond to anticancer therapy, according to a presentation at the 2019 Association for Molecular Pathology Annual Meeting and Expo.

Choosing Between Systemic Therapy and TACE for HCC

November 29, 2019

Clinical Articles

What is the ideal first-line therapy for nonresectable, non– transplant eligible, liver-only hepatocellular carcinoma? In a debate at the 2019 Gastrointestinal Oncology Conference, Mark Yarchoan, MD, had the unenviable task of convincing the audience that systemic therapy was the way to go.

MRTX849 Shows Safety, Tolerability in Treating KRAS G12C

November 29, 2019

Clinical Articles

In patients whose solid tumors harbor a mutation in KRAS G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.

Guidelines Direct Pretransplant Work-Up and Illustrate GVHD Challenges

December 04, 2019

Clinical Articles

New clinical practice guidelines for HCT have been published by the National Comprehensive Cancer Network. The guidelines provide step-by-step information on best practices in evaluating patients for HCT and managing complications.

A Growing Number of Immunotherapeutics Are Taking Hold in CRC

December 03, 2019

Clinical Articles

Immotherapuetic agents have grown in popularity for treating mismatch repair–deficient (dMMR) metastatic colorectal cancer, becoming the standard of care in the second line, Howard Hochster, MD, told an audience at the 2019 Gastrointestinal Oncology Conference. Furthermore, ongoing clinical trials suggest that these agents may play a larger role in treating CRC going forward.

Shifting the Focus to Newer Technologies for Immunotherapy Response

December 03, 2019

Clinical Articles

It is clear that cancer immunotherapy has progressed dramatically over the past 10 years, with over 20 FDA approvals for immune checkpoint receptor inhibitors targeting PD-1 and CTLA-4. However, we are still awaiting the next major advance in these inhibitory receptor targets that yields clinical benefit. In the meantime, additional advances have appeared.

Tipifarnib Yields 100% Disease Control in HRAS-Mutant Head and Neck Squamous Cell Carcinoma

December 03, 2019

Clinical Articles

The signal transduction inhibitor tipifarnib induced disease control in all patients with HRAS-mutant head and neck squamous cell carcinoma and a high variant allele frequency, according to preliminary results of a phase II trial presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.

2020 Meeting on Cutaneous Malignancies Will Address Next Steps For Immunotherapy

December 03, 2019

Clinical Articles

Treatment with immunotherapy has become ingrained in the standard of care for treating patients with melanoma, but investigators continue to research new combinations and treatment strategies that can improve patients outcomes. One approach that has generated a great deal of interest and is a significant focus of ongoing trials involves adjuvant and neoadjuvant therapy, according to Jeffrey S. Weber, MD, PhD.

Breakthrough Therapy Selumetinib Exhibits Objective Response, Clinical Benefit in Adults With Neurofibromas

December 04, 2019

Clinical Articles

Selumetinib, an oral MEK inhibitor, demonstrated clinical benefit without significant toxicity in adult patients affected by symptomatic neurofibromatosis type 1 (NF1) with associated plexiform neurofibromas (PN), according to Geraldine O’Sullivan Coyne, MD, PhD, in a preconference briefing of the 2019 American Association for Cancer Research–National Cancer Institute–European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics, held October 26 to 30, 2019, in Boston, Massachusetts.